Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBITDA (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed EBITDA for 10 consecutive years, with $9.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 160.42% year-over-year to $9.3 million, compared with a TTM value of -$62.9 million through Dec 2025, up 27.65%, and an annual FY2025 reading of -$62.7 million, up 27.72% over the prior year.
  • EBITDA was $9.3 million for Q4 2025 at Zevra Therapeutics, up from $4.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $9.3 million in Q4 2025 and bottomed at -$71.0 million in Q2 2025.
  • Average EBITDA over 5 years is -$11.7 million, with a median of -$7.9 million recorded in 2022.
  • The sharpest move saw EBITDA surged 284.37% in 2021, then plummeted 590.21% in 2023.
  • Year by year, EBITDA stood at -$2.8 million in 2021, then tumbled by 225.58% to -$9.3 million in 2022, then plummeted by 58.55% to -$14.7 million in 2023, then decreased by 5.08% to -$15.4 million in 2024, then surged by 160.42% to $9.3 million in 2025.
  • Business Quant data shows EBITDA for ZVRA at $9.3 million in Q4 2025, $4.1 million in Q3 2025, and -$71.0 million in Q2 2025.